Last reviewed · How we verify
raloxifene HCI and alendronate Na
This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.
This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density. Used for Postmenopausal osteoporosis prevention and treatment.
At a glance
| Generic name | raloxifene HCI and alendronate Na |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Selective estrogen receptor modulator (SERM) + bisphosphonate combination |
| Target | Estrogen receptor (raloxifene); osteoclast farnesyl pyrophosphate synthase (alendronate) |
| Modality | Small molecule |
| Therapeutic area | Bone health / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Raloxifene acts as a selective estrogen receptor modulator (SERM) that mimics estrogen effects on bone tissue, reducing bone turnover and resorption. Alendronate is a bisphosphonate that binds to hydroxyapatite in bone and inhibits osteoclast function, further suppressing bone resorption. Together, these complementary mechanisms work synergistically to increase bone mineral density and reduce fracture risk in postmenopausal women.
Approved indications
- Postmenopausal osteoporosis prevention and treatment
Common side effects
- Hot flashes
- Leg cramps
- Gastrointestinal upset (nausea, dyspepsia)
- Musculoskeletal pain
- Venous thromboembolism (raloxifene component)
Key clinical trials
- EVA: Evista Alendronate Comparison (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- raloxifene HCI and alendronate Na CI brief — competitive landscape report
- raloxifene HCI and alendronate Na updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI